CN115768460A - 长效glp-1/gip双重激动剂 - Google Patents

长效glp-1/gip双重激动剂 Download PDF

Info

Publication number
CN115768460A
CN115768460A CN202180042855.9A CN202180042855A CN115768460A CN 115768460 A CN115768460 A CN 115768460A CN 202180042855 A CN202180042855 A CN 202180042855A CN 115768460 A CN115768460 A CN 115768460A
Authority
CN
China
Prior art keywords
ser
polypeptide
pharmaceutically acceptable
lys
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180042855.9A
Other languages
English (en)
Chinese (zh)
Inventor
R·森纳缇
V·S·布拉德
M·纳塔拉扬
D·R·乔希
M·H·甘地
C·T·吉瓦尼
A·提瓦里
K·H·索尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of CN115768460A publication Critical patent/CN115768460A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202180042855.9A 2020-06-22 2021-06-21 长效glp-1/gip双重激动剂 Pending CN115768460A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN202021026360 2020-06-22
IN202021026360 2020-06-22
IN202121002838 2021-01-20
IN202121002838 2021-01-20
PCT/IB2021/055457 WO2021260530A1 (en) 2020-06-22 2021-06-21 Long acting glp-1/gip dual agonists

Publications (1)

Publication Number Publication Date
CN115768460A true CN115768460A (zh) 2023-03-07

Family

ID=76891103

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180042855.9A Pending CN115768460A (zh) 2020-06-22 2021-06-21 长效glp-1/gip双重激动剂

Country Status (18)

Country Link
US (2) US20230241178A1 (https=)
EP (1) EP4146248A1 (https=)
JP (1) JP7849310B2 (https=)
KR (1) KR20230023658A (https=)
CN (1) CN115768460A (https=)
AU (1) AU2021296376A1 (https=)
BR (1) BR112022025615A2 (https=)
CA (1) CA3183358A1 (https=)
CL (1) CL2022003654A1 (https=)
CO (1) CO2022018464A2 (https=)
EC (1) ECSP22095556A (https=)
IL (1) IL299195A (https=)
JO (1) JOP20220344A1 (https=)
MX (1) MX2022016032A (https=)
PE (1) PE20230861A1 (https=)
PH (1) PH12022553526A1 (https=)
TW (1) TW202216746A (https=)
WO (1) WO2021260530A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20231309A1 (es) * 2020-10-17 2023-08-24 Sun Pharmaceutical Ind Ltd Agonistas duales glp-1/gip
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
US12281149B2 (en) 2021-05-13 2025-04-22 Carmot Therapeutics, Inc. Modulators of G-protein coupled receptors
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
WO2024098718A1 (zh) * 2022-11-07 2024-05-16 内蒙古博睿精创科技有限公司 一种新型长效多肽化合物、组合物及其应用
CN120865433A (zh) * 2022-12-21 2025-10-31 勃林格殷格翰国际有限公司 Glp1/gip/npy2受体的三重激动剂
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
KR20260022948A (ko) 2023-06-09 2026-02-20 썬 파마슈티컬 인더스트리스 리미티드 Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025163615A1 (en) 2024-01-31 2025-08-07 Sun Pharmaceutical Industries Ltd. High level production of glp1 analogues
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164483A1 (en) * 2012-05-03 2013-11-07 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
CN107207576A (zh) * 2015-01-09 2017-09-26 伊莱利利公司 Gip和glp‑1共激动剂化合物
WO2019193576A1 (en) * 2018-04-05 2019-10-10 Sun Pharmaceutical Industries Limited Novel glp-1 analogues

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120123443A (ko) * 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CN119499352A (zh) 2018-07-23 2025-02-25 伊莱利利公司 使用gip/glp1共激动剂用于糖尿病的方法
KR20240051304A (ko) * 2018-07-23 2024-04-19 일라이 릴리 앤드 캄파니 Gip/glp1 공효능제 화합물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164483A1 (en) * 2012-05-03 2013-11-07 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
CN107207576A (zh) * 2015-01-09 2017-09-26 伊莱利利公司 Gip和glp‑1共激动剂化合物
WO2019193576A1 (en) * 2018-04-05 2019-10-10 Sun Pharmaceutical Industries Limited Novel glp-1 analogues

Also Published As

Publication number Publication date
EP4146248A1 (en) 2023-03-15
MX2022016032A (es) 2023-04-19
US20230241178A1 (en) 2023-08-03
JP7849310B2 (ja) 2026-04-21
CO2022018464A2 (es) 2023-03-17
AU2021296376A1 (en) 2022-12-08
US20240424063A1 (en) 2024-12-26
PH12022553526A1 (en) 2024-01-22
CA3183358A1 (en) 2021-12-30
WO2021260530A1 (en) 2021-12-30
KR20230023658A (ko) 2023-02-17
JP2023530515A (ja) 2023-07-18
TW202216746A (zh) 2022-05-01
BR112022025615A2 (pt) 2023-01-17
JOP20220344A1 (ar) 2022-12-20
AU2021296376A8 (en) 2022-12-22
CL2022003654A1 (es) 2023-08-04
IL299195A (en) 2023-02-01
PE20230861A1 (es) 2023-05-30
ECSP22095556A (es) 2023-01-31

Similar Documents

Publication Publication Date Title
CN115768460A (zh) 长效glp-1/gip双重激动剂
TW202229323A (zh) 新型glp-1/gip雙重促效劑
RU2589255C2 (ru) Модифицированные вазоактивные интестинальные пептиды
JP7250814B2 (ja) 新規ｇｌｐ－１類似体
CN102532301B (zh) 一类新型的Exendin-4类似物及其制备方法
CN101213209A (zh) 新颖化合物及它们对进食行为的影响
US20070244041A1 (en) Peptide Yy Analogues
CN116143884B (zh) 一类长效GLP-1/glucagon/GIP受体三重激动剂及其应用
EP3882263A1 (en) Glucagon-derived peptide and use thereof
CN101255191A (zh) 微波促进固相合成胰高血糖素样肽-1(glp-1)类似物及其应用
KR20230008846A (ko) 이중 수용체 아고니즘 작용을 갖는 폴리펩티드 유도체 및 그 용도
CN101337989A (zh) 一类新型胰高血糖素样肽-1(glp-1)类似物及其应用
CN118843638A (zh) Crf2受体激动剂及其在治疗中的用途
JP4477506B2 (ja) ペプチド及びこれを含む医薬組成物
CN108359005A (zh) 非洲爪蟾glp-1类似物及其用途
CN107987152A (zh) 霉酚酸-非洲爪蟾胰高血糖素样肽-1缀合肽及其用途
CN115873096B (zh) 一种胰高血糖素糖肽-1和胰高血糖素受体双重激动多肽及其应用
CN101342365A (zh) 一类新型胰高血糖素样肽-1(glp-1)类似物的用途
CN116514952B (zh) 一类glp-1类似物及其应用
CN115819619B (zh) 一类glp-1/y2受体双重激动剂及其应用
CN119488582A (zh) 一种glp-1和pyy孪药及其制备方法和应用
EA053025B1 (ru) Двойные агонисты glp-1/gip

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination